High Magnitude of Fecal Carriage of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae at Debre Berhan Comprehensive Specialized Hospital, Ethiopia

Demissew Shenkute¹, Melese Hailu Legese², Berhanu Yitayew¹, Asaye Mitiku³, Getabalew Engidaye⁴, Saba Gebremichael⁵, Daniel Asrat⁶, Yimtubezinash Woldeamanuel⁶

¹Department of Medical Laboratory Science, College of Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia; ²Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; ³Department of Medical Laboratory Science, College of Medicine and Health Sciences, Dilla University, Dilla, Ethiopia; ⁴Department of Medical Laboratory Science, Debre Berhan Health Science College, Debre Berhan, Ethiopia; ⁵Department of Medical Laboratory Science, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia; ⁶Department of Microbiology, Immunology, and Parasitology, College of Health Sciences Addis Ababa University, Addis Ababa, Ethiopia

Correspondence: Demissew Shenkute, Email demissewshen@gmail.com

Background: Gastrointestinal colonization rate of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) is the major risk factor for infection and dissemination of resistance clones in healthcare facilities. This study aimed to investigate the magnitude of the fecal carriage of ESBL-PE and associated factors among hospitalized patients at Debre Berhan Comprehensive Specialized Hospital, North Shoa, Amhara Regional State, Ethiopia.

Methods: A hospital-based cross-sectional study was conducted among 383 hospitalized patients from November 2020 to March 2021. Stool sample or rectal swab was aseptically collected and cultured on different culture media for isolation of Enterobacteriaceae. Identification was done by conventional biochemical tests. Screening of extended-spectrum beta-lactamase (ESBL) production was done by using cefotaxime and ceftazidime and confirmed by the combination disk method. Data analysis was performed by Statistical Package for Social Sciences software version 25 and a P-value ≤0.05 was considered as statistically significant.

Results: From the total of 383 hospitalized patients, a total of 347 Enterobacteriaceae were isolated. The overall gastrointestinal colonization rate of ESBL-PE was 47.3% (164/347). The predominant ESBL-PE were E. coli 54.9% (90/164) and K. pneumoniae 33.5% (55/164). The overall multi-drug resistance rate (MDR) was 87.8% (305/347). The highest resistance was observed to ampicillin (98.3%), followed by gentamicin (80.7%), and tetracycline (73.3%), respectively. ESBL-PE were highly susceptible to meropenem (90.2%) and imipenem (89.0%). History of antibiotic use in the past 3 months (p<0.001), admission in the neonatal intensive care unit (p=0.023), and presence of chronic disease (p<0.001) were independently associated with fecal carriage of ESBL-PE.

Conclusion: The magnitude of ESBL-PE and MDR was high in the study area. Meropenem and imipenem were active against ESBL-PE. Therefore, strict infection control measure is needed in the study area to limit the infection and dissemination of ESBL-PE.

Keywords: fecal carriage, extended-spectrum beta-lactamase, Enterobacteriaceae, Ethiopia, hospitalized patients, associated factors

Introduction

The Enterobacteriaceae family is a large and diverse collection of Gram-negative rods and is the most common cause of both community and hospital-acquired infections. They are associated with a variety of syndromes including gastritis, urinary tract infections (UTIs), bloodstream infections, pneumonia, peritonitis, meningitis, and device-associated infections.

Antibacterial agents of the beta-lactam group are the commonly prescribed antibiotics for the treatment of infections caused by multi-drug resistant Enterobacteriaceae (MDR-E). However, the emergence of resistance to beta-lactam antibiotics has become a major challenge in the treatment of severe nosocomial infection. The production of beta-lactamases is the main mechanism of resistance to beta-lactam antibiotics in Enterobacteriaceae. Among the beta-
lactamases, the production of extended-spectrum beta-lactamases (ESBLs) are the most common. ESBL enzymes can break or hydrolyze many beta-lactam antibiotics including penicillins, cephalosporins, and monobactams except for cephemycins, clavulanate, and carbapenems.3

The emergence phenomenon of ESBL-PE has consequently increased the consumption of carbapenems. These antibacterial agents are a crucial treatment option for life-threatening nosocomial or hospital-acquired infections. The rise of carbapenem resistance may imperil or halt the advancement of current medical treatments. It is clear that very few novel antibiotics will be discovered in the near future, making the issue of carbapenem-resistant Enterobacteriaceae of primary importance worldwide.1

Fecal carriage of ESBL-PE is the major risk factor for infection with antibiotic-resistant bacteria for hospitalized patients since the bacteria can spread from colonized persons to others by hand carriage as well as contaminated food and water.4–6 The problem is worrying because ESBL enzymes can hydrolyze almost all beta-lactams except carbapenems and cephamycins. In addition, these enzymes are usually encoded by genes found on highly mobile genetic elements such as plasmids, providing the ability for clonal and horizontal transfer. These plasmids can also confer resistance genes to other classes of antibiotics including aminoglycosides, trimethoprim, sulphonamides, tetracyclines, and chloramphenicol.7

The gastrointestinal tract is the principal reservoir for Enterobacteriaceae infections, whether they are acquired in the hospital or the community. Additionally, the gastrointestinal tract is the place where the exchange of resistance genes between bacteria happens, and antibiotic treatment selects the overgrowth of resistant bacteria. Consequently, colonization by ESBL-PE is one of the most important risk factors for antibiotic-resistant bacterium infection.8 These infections pose a great challenge which increases hospital stay, and cost and leads to increased morbidity and mortality rates due to the limited therapeutic options.9 It has been reported that infections caused by ESBL-PE have a fatality rate that ranges from 42% to 100.10

Fecal carriage of ESBL-PE has been increasingly reported worldwide over the last decade. The highest carriage prevalence has been described in Asia whereas prevalence rates are lower in Europe and North America.11,12 However, data on ESBL-PE in Eastern Africa including Ethiopia is scarce.13

Although antimicrobial resistance (AMR) is a global threat; the burden is higher in low-income countries like Sub-Saharan Africa (SSA) where, widespread self-medication, overcrowding of hospitals, absence of antibiotic prescription guidelines, poor infection control practices, and poor hygiene and antibiotic misuse is common.14

Researches have been undertaken in the context of infection caused by ESBL-PE in Ethiopia.15 However, little is known regarding the gastrointestinal carriage rate of ESBL-PE in hospitalized patients.16,17 Local epidemiological data on the carriage of ESBL-PE is very important to prevent and control nosocomial infection and the spread of antimicrobial resistance in hospitals. Hence, this study aimed to investigate the fecal carriage of ESBL-PE and associated factors among hospitalized patients in Debre Berhan Comprehensive Specialized Hospital (DBCSH), North Shoa, Amhara Regional State, Ethiopia.

Materials and Methods

Study Setting

A hospital-based cross-sectional study was conducted from November 2020 to March 2021. The study was conducted at DBCSH in Amhara Regional State, Central Ethiopia, Debre Berhan town which is located 130 Km far from the capital city of the country, Addis Ababa. The hospital provides health services for over two million people of Amhara, Afar, and two woredas of Oromia regions with more than 200 beds.

Study Population

All patients including neonates, infants, children, and adults who were admitted for ≥ 48 hours at DBCSH during the study period were the study population. All patients who were admitted for less than 48 hours, critically ill patients, and those unable to give a specimen were excluded from the study.
Data Collection

Sociodemographic Data

Sociodemographic and clinical data were collected using pre-tested structured questionnaires after obtaining informed consent from adult participants or consent from parents/guardians and assent from participants for those who were younger than 18 years. Clinical data of the patients such as the history of hospitalization in the past 12 months, history of antibiotic use in the past 3 months, and other clinical data were collected from their medical records.

Sample Collection

Stool sample was collected using a clean stool container. After collection, the stool was immediately taken to the Microbiology laboratory for analysis. A rectal swab was collected from neonates and participants that cannot give stool by an experienced nurse. Then the swab was put in a test tube with Cary-Blair transport media and transported to the Microbiology laboratory for further bacteriological analysis.

Isolation and Identification

Each stool sample/rectal swab was first inoculated onto MacConkey agar (SRL. Pvt. Ltd. India) and incubated aerobically at 37°C for 18 to 24 hrs. Then, each culture plate was examined for the growth of Enterobacteriaceae. Lactose fermenters and non-lactose fermenters were characterized on MacConkey agar and then non-lactose fermenter colonies were inoculated on Xylose-Lysine Deoxycholate (XLD) agar (HiMedia. India) to observe further characteristics. Finally, pure colonies were taken for identification. All isolated Enterobacteriaceae were characterized by colony characteristics and identified by conventional biochemical tests namely, indole, citrate utilization, triple sugar iron, lysine decarboxylase, urea hydrolysis, motility, and mannitol fermentation.

Antimicrobial Susceptibility Test

Antimicrobial susceptibility testing was performed by the Kirby-Bauer disk diffusion method per Clinical Laboratory Standard Institute (CLSI) guidelines on Mueller Hinton agar (MHA) (Hi-Media: India). The zones of inhibition were interpreted according to CLSI guidelines. The antibiotic disks used in this study were ampicillin (AM:10μg), cefoxitin (FOX:10μg), gentamicin (GM: 10μg), ciprofloxacin (CIP: 5μg), trimethoprim-sulfamethoxazole (STX: 1.25/23.75 μg), imipenem (IPM: 10μg), meropenem (MEP: 10 μg), amoxicillin-clavulanic acid (AMC: 30μg), cefotaxime (CTX:30 μg), ceftazidime (CAZ:30μg), ceftriaxone (CRO:30μg), tetracycline (TE:30μg), cefepime (FEP:30μg), and chloramphenicol (C:30μg). All antibiotics were (Oxoid, United Kingdom).

Multi-Drug-Resistance Isolates

The isolates that were resistant to one or more antibiotics in three or more classes of antimicrobials agents were considered as multi-drug resistance Enterobacteriaceae.

Screening for Potential ESBL Producing Enterobacteriaceae

Enterobacteriaceae that showed an inhibition zone size of ≤ 22 mm with ceftazidime (30 μg), and/or ≤ 27mm with cefotaxime (30 μg) were considered as potential ESBL producers CLSI guidelines.

Phenotypic Confirmation of ESBL Production

Ceftazidime (30 μg) and cefotaxime (30 μg) alone, as well as their combination with Clavulanic acid (30 μg g/10 μg) acid, were placed at an appropriate distance on the MHA plate that was inoculated with a bacterial suspension of 0.5 McFarland turbidity standard and incubated overnight (18–24 hrs) at 37°C. Enterobacteriaceae that showed an increase in the inhibition zone diameter of ≥ 5mm for combination disks versus ceftazidime or cefotaxime disk alone were confirmed as ESBL producers.

Quality Control

Standard Operating Procedures (SOP) were strictly followed for each procedure. The stool specimen was processed and transported soon after receipt as possible. If there is a delay in processing the specimen, it was placed in the refrigerator.
Before using the media, reagents, and antibiotic disks, the expiration dates were checked. Following sterility testing, the culture media was visually evaluated for cracks and thickness, as well as the presence of freezing, bubbles, and contaminants. For ESBLs confirmatory test, ESBLs positive *K. pneumoniae* ATCC 700603 and ESBLs negative *E. coli* ATCC 25922 control strains were used. The data collection form was checked for its completeness and accuracy before recording the data. Culture and antibiotics susceptibility test results were recorded carefully before entering.

**Statistical Analysis**

The data were entered into Epi Data version 3.1 and double-checked and cleaned before analysis. Then the data was exported to Statistical Package for Social Sciences (SPSS) version 25 for analysis. The descriptive statistics (median, percentages, or frequency) were calculated. Bivariant logistic regression analysis was used to observe the relationship between the dependent variable and independent variables. Variables that showed P-value ≤ 0.25 in bivariant logistic regression analysis were selected for further analysis using multivariable logistic regression models. Variables that showed a p-value ≤ 0.05 by multivariable logistic regression models were considered as statistically significant.

**Ethical Considerations**

The study was reviewed and approved by the Departmental Research and Ethics Review Committee (DRERC) of Microbiology, Parasitology, and Immunology, School of Medicine, College of Health Sciences; Addis Ababa University (Ref. no. DRERC /005/2020). A written permission letter was also obtained from the Debre Berhan Comprehensive Specialized Hospital. The purpose and procedures of the study were explained to the study participants and parents or guardians during the study period by providing all information about the study in an information sheet. For participants who cannot read and write, the information sheet was read to them, and a witness signed that the process had been conducted appropriately. The confidentiality of all study participants was maintained This manuscript is prepared from the MSc thesis. This study also was conducted per the Declaration of Helsinki.

**Results**

**Sociodemographic Characteristics of the Study Participants**

A total of 383 study participants were included in the study. Out of these 72.8% (n=265/383) were adults (median age =41 years old, interquartile range =30 to 55 years), 17% (n=65/383) were children (median age=1.25 years, interquartile range=1 to 2.5 years) and 10.2% (n=39/383) were neonates (median age =7 days, interquartile range =4 to 11 days). Nearly half of the study participants (50.4%) were females. The majority of (61.9%) of the study participants were living in rural areas (Table 1).

**Clinical Profile of the Study Participants**

Of the total of 383 study participants, 27.9% (n=107/383) had a history of antibiotic usage in the past 3 months while 23.8% (n=91/383) had a history of hospitalization in the past twelve months. It was found that 8.9% (n=34/383) were admitted due to sepsis. More than one-fourth of the participants 27.2% (n=104/383) were admitted to the medical ward (Table 2).

**Bacterial Identification and Antimicrobial Resistance Pattern**

A total of 347 *Enterobacteriaceae* were isolated in this study. The most predominant isolates were *E. coli* 63.7% (n=221/347) followed by *K. pneumoniae* 26.5% (n=92/347), and *E. cloacae* 3.5% (n=12/347) respectively (Figure 1).

Antimicrobial susceptibility testing was done for all *Enterobacteriaceae* isolates against fourteen selected antibiotics. The highest level of resistance was observed to ampicillin (98.3%) followed by gentamicin (80.7%), tetracycline (73.3%), and trimethoprim-sulfamethoxazole (64.8%) respectively. A low level of resistance was recorded against carbapenems (imipenem (6.3%) and meropenem (6.9%)) followed by chloramphenicol (15.9%) (Table 3).
**E. coli** isolates showed the highest resistance to ampicillin (97.3%) followed by gentamicin (73.3%), tetracycline (67.9%), and trimethoprim-sulfamethoxazole (54.8%). Among **K. pneumoniae** isolates (15.2%) were resistant to meropenem (Table 3).

Multi-drug resistance (resistance to at least 3 antibiotics in a different class) was observed in 87.6% (n=305/347). **K. oxytoca, E. cloacae, Citrobacter spp, M. morganii, K. ozaenae, and C. diversus** showed 100% MDR level (Table 4).

### The Magnitude of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae

The overall magnitude of ESBL-PE was 47.3% (n=164/347) which accounts for **E. coli** 25.9% (n=90/347) followed by **K. pneumoniae** 15.9% (n=55/347) and other **Enterobacteriaceae** 5.5% (n=19/347).

The distribution of ESBL-PE and non-ESPL-PE was varied among **Enterobacteriaceae** species. The highest ESBL-PE was observed in **K. oxytoca** (88.9%,8) followed by **K. pneumoniae** (59.8%,55) and **E. cloacae** (50.0%,6) respectively (Figure 2).

Non-ESBL producing **Enterobacteriaceae** were more sensitive to antibiotics than ESBL-PE. Meropenem, imipenem, and chloramphenicol were active antibiotics for ESBL-PE with a sensitivity of 90.2%, 89.0%, and 76.2% respectively (Figure 3).

Of 305 MDR-E (53.3%) were ESBL mediated MDR. Among the total 181 MDR **E. coli** (49.2%) were ESBL producers (Table 5).

### Factors Associated with Fecal Carriage of ESBL-PE

In bivariate logistic regressions analysis, all independent variables including socio-demographic and clinical data were assessed to determine whether they were contributing factors or not for fecal carriage of ESBL-PE. Admission in NICU ward [AOR= 4.86, 95% CI: (1.24–18.96)], history of antibiotic use in the past 3 months [AOR= 4.68, 95% CI: (2.28–9.58)]

---

**Table 1** Sociodemographic Characteristics of Study Participants at Debre Berhan Comprehensive Specialized Hospital from November 2020 to March 2021

| Variables                  | Categories        | Number (n=383) | Percent (%) |
|----------------------------|-------------------|----------------|-------------|
| Sex                        | Male              | 190            | 49.6        |
|                            | Female            | 193            | 50.4        |
| Age group                  | Neonate           | 39             | 10.2        |
|                            | Children          | 65             | 17.0        |
|                            | Adults            | 279            | 72.8        |
| Residence                  | Rural             | 237            | 61.9        |
|                            | Urban             | 146            | 38.1        |
| Adults Marital status      | Married           | 245            | 64.0        |
|                            | Single            | 31             | 8.1         |
|                            | Divorced          | 3              | 0.8         |
| Educational status         | Illiterate        | 245            | 64.0        |
|                            | Primary           | 69             | 18.0        |
|                            | Secondary         | 36             | 9.4         |
|                            | Higher and above  | 33             | 8.6         |
| Adults occupational status | Unemployed        | 7              | 28.7        |
|                            | Government employed | 33           | 8.6         |
|                            | Daily labour      | 3              | 0.8         |
|                            | Farmer            | 65             | 17.0        |
|                            | Housewife         | 82             | 21.4        |
|                            | Others            | 90             | 23.5        |

---

*E. coli* isolates showed the highest resistance to ampicillin (97.3%) followed by gentamicin (73.3%), tetracycline (67.9%), and trimethoprim-sulfamethoxazole (54.8%). Among **K. pneumoniae** isolates (15.2%) were resistant to meropenem (Table 3).

Multi-drug resistance (resistance to at least 3 antibiotics in a different class) was observed in 87.6% (n=305/347). **K. oxytoca, E. cloacae, Citrobacter spp, M. morganii, K. ozaenae, and C. diversus** showed 100% MDR level (Table 4).
Table 2 Clinical Profile of the Study Participants at Debre Berhan Comprehensive Specialized Hospital from November 2020 to March 2021

| Variables                              | Categories      | Frequency | Percent (%) |
|----------------------------------------|-----------------|-----------|-------------|
| History of antibiotic use in the past 3 months | Yes             | 107       | 27.9        |
|                                        | No              | 276       | 72.1        |
| History of hospitalization in the past 12 months | Yes             | 91        | 23.8        |
|                                        | No              | 292       | 76.2        |
| Previous history of hospital stays     | 3–7 days        | 22        | 5.7         |
|                                        | 8–14 days       | 48        | 12.5        |
|                                        | >14 days        | 21        | 5.5         |
| Previous ICU stay                      | Yes             | 1         | 0.3         |
|                                        | No              | 382       | 99.7        |
| Number of bed/rooms                    | 2–4             | 48        | 12.5        |
|                                        | 5–8             | 335       | 87.5        |
| Number of patient/rooms                | 2–4             | 140       | 36.6        |
|                                        | 5–8             | 243       | 63.4        |
| Reason for admission                   | Sepsis          | 34        | 8.9         |
|                                        | UTI             | 13        | 3.4         |
|                                        | Pneumonia       | 22        | 5.7         |
|                                        | Meningitis      | 10        | 2.6         |
|                                        | Malnutrition    | 21        | 5.5         |
|                                        | Heart failure   | 28        | 7.3         |
|                                        | Peptic ulcer disease | 16 | 4.2 |
|                                        | Others          | 239       | 62.4        |
| History of invasive procedure in the past 3 months | Yes             | 46        | 12.0        |
|                                        | No              | 337       | 88.0        |
| Types of invasive procedure            | Catherization   | 32        | 8.4         |
|                                        | Surgery         | 14        | 3.6         |
| Admission ward                         | Neonatal ICU    | 39        | 10.2        |
|                                        | Paediatric      | 63        | 16.4        |
|                                        | Medical         | 104       | 27.2        |
|                                        | Surgery         | 92        | 24.0        |
|                                        | Adult ICU       | 7         | 1.8         |
|                                        | Gynaecology and obstetrics | 53 | 13.8 |
|                                        | Ophthalmology   | 25        | 6.5         |
| Ward stays                             | 3–7 days        | 326       | 85.1        |
|                                        | 8–14 days       | 44        | 11.5        |
|                                        | >15 days        | 13        | 3.4         |
| Chronic disease                        | Yes             | 85        | 22.2        |
|                                        | No              | 298       | 77.8        |
| Types of chronic disease               | Diabetes        | 23        | 6.0         |
|                                        | HIV             | 20        | 5.2         |
|                                        | Hypertension    | 31        | 8.1         |
|                                        | Haematological malignancy | 1 | 0.3 |
|                                        | Tuberculosis    | 6         | 1.5         |
|                                        | Kidney disease  | 1         | 0.3         |
|                                        | Heart disease   | 3         | 0.8         |
and presence of chronic disease [AOR= 3.65, 95% CI: (1.87–7.13)] showed statistical significance for fecal carriage of ESBL-PE (Table 6).

Discussions

Gastrointestinal carriage of ESBL-PE become a major challenge for hospitalized patients worldwide. Infections caused by ESBL-PE are usually multi-drug resistant making the treatment option challenging. Colonization with ESBL-PE is the main threat that can lead to cross-transmission and self-infection among hospitalized patients. This research addresses the fecal carriage of ESBL-PE and associated factors among hospitalized patients.

A total of 347 Enterobacteriaceae were isolated in this study. Out of these, the highest proportion was E. coli (63.6%) followed by K. pneumoniae (26.5%), accounting for the two most common normal flora of the gastrointestinal tract. The result was comparable with the previous study done in Addis Ababa, Ethiopia which showed that E. coli (79.7%) was the most common isolate followed by K. pneumoniae (19.7%). Similarly, a study from Gondar, Ethiopia showed that E. coli (59.7%) and K. pneumoniae (16.1%) were frequently identified Enterobacteriaceae. Additionally, a report from Turkey also showed E. coli (94.5%), and K. pneumoniae (5.1%) as predominant isolates. Other species commonly isolated following E. coli and K. pneumoniae in this study were E. cloacae.

Among the fourteen antibiotics tested in this study, the highest level of resistance was observed to ampicillin (98.3%) followed by gentamicin (80.7%), tetracycline (73.3%), and trimethoprim-sulfamethoxazole (64.8%), respectively. A low level of resistance rate was recorded against the last-resort antibiotics, imipenem (6.3%) and meropenem (6.9%). Comparable results were also reported from Arba Minch, Ethiopia, Tanzania, Egypt, and Morocco. The reason for the high level of resistance to ampicillin might be being cheap and the first line of treatment and thus highly misused. In the hospital, there was no antibiotic susceptibility screening service for isolates from patients and therefore the observed high resistance prevalence against these antibiotics could also be associated with empirical treatment. The finding highlights the importance of the implementation of an antimicrobial stewardship program in healthcare facilities to mitigate the spread of antimicrobial resistance and limit the consumption of antibiotics.

There were distinct resistance patterns among the different bacterial species. E. coli isolates showed the highest resistance to ampicillin (97.3%) followed by gentamicin (73.3%), tetracycline (67.9%), and trimethoprim-sulfamethoxazole (54.8%). This was in close agreement with the study conducted in Addis Ababa, Ethiopia, Gondar, Ethiopia and Tanzania. In K. pneumoniae the highest rate of resistance was recorded against ampicillin (100%), followed by gentamicin (95.7%), trimethoprim-sulfamethoxazole (84.8%), and tetracycline (80.4%). This was
| Isolates           | AMP  | FOX  | GM   | CIP  | STX  | IPM  | MEP  | AMC  | CTX  | CAZ  | CRO  | TE   | FEP  | C    |
|-------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|-----|
| E. coli (n=221)   | 215(97.3) | 42(19.0)| 162(73.3) | 66(29.9) | 121(54.8) | 6(2.7) | 6(2.7) | 103(46.6) | 94(42.5) | 66(29.9) | 93(42.) | 150(67.9) | 35(15.8) | 19(8.6) |
| Citrobacter spp (n=4) | 4(100.0) | 2(50.0) | 4(100.0) | 1(25.0) | 3(75.0) | 0(0.0) | 0(0.0) | 2(50.0) | 3(75.0) | 2(50.0) | 3(75.0) | 4(100.0) | 0(0.0) | 0(0.0) |
| K. pneumoniae (n=92) | 92(100.0) | 3(38.0) | 88(95.7) | 54(58.7) | 78(84.8) | 12(13.0) | 14 (15.2) | 68(73.9) | 63(68.5) | 50(54.3) | 65(70.7) | 74(80.4) | 34(37.0) | 25(27.2) |
| E. cloacae (n=12) | 12(100.0) | 6(50.0) | 10(83.3) | 5(41.7) | 11(91.7) | 0(0.0) | 0(0.0) | 8(66.8) | 8(66.7) | 7(58.3) | 8(66.7) | 12(100.0) | 4(33.3) | 7(58.3) |
| K. oxytoca (n=9)  | 9(100.0) | 4(44.4) | 8(88.9) | 6(66.7) | 7(77.8) | 4(44.4) | 4(44.4) | 7(77.8) | 9(100.0) | 9(100.0) | 9(100) | 7(77.8) | 5(55.6) | 2(22.2) |
| C. diversus (n=5) | 5(100.0)| 1(20.0) | 5(100.0) | 0(0.0) | 3(60.0) | 0(0.0) | 0(0.0) | 5(100.0) | 4(100.0) | 3(60.0) | 2(40.0) | 5(100.0) | 0(0.0) | 0(0.0) |
| M. morganii (n=2) | 2(100.0) | 2(100.0) | 2(100.0) | 0(0.0) | 1(50.0) | 0(0.0) | 0(0.0) | 2(100.0) | 2(100.0) | 2(100.0) | 0(0.0) | 2(100.0) | 0(0.0) | 2(100.0) |
| P. stuartii (n=1) | 1(100.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(100.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) |
| K. ozaenae (n=1)  | 1(100.0) | 0(0.0) | 1(100.0) | 1(100.0) | 1(100.0) | 0(0.0) | 0(0.0) | 1(100.0) | 1(100.0) | 1(100.0) | 1(100) | 1(100.0) | 0(0.0) | 0(0.0) |
| Total resistance (n=347) | 341(98.3) | 92(26.5) | 280(80.7) | 133(38.3) | 225(64.8) | 22(6.3) | 24(6.9) | 196(56.5) | 184(53.0) | 140(40.3) | 181(52.2) | 255(73.3) | 78(22.5) | 55(15.9) |

**Abbreviations:** AMP, ampicillin; FOX, cefoxitin; GM, gentamicin; CIP, ciprofloxacin; STX, trimethoprim-sulfamethoxazole; IPM, imipenem; MEP, meropenem; AMC, amoxicillin-clavulanic acid; CTX, cefotaxime; CAZ, ceftazidime; CRO, ceftriaxone; TE, tetracycline; FEP, cefepime; C, chloramphenicol.
This high resistance pattern among the isolates may be due to inappropriate prescription of antibiotics, and self-medication practices. The increase of AMR is a threat for many developing countries because of the absence of detection methods due to a lack of resources and poor infrastructure. Poor personal hygiene due to different factors such as water shortage and lack of knowledge may also contribute to the increased resistance prevalence in the current study. Previously it was reported that if there are poor hand hygiene resistant bacteria can spread from one patient to another via healthcare workers’ contaminated hands predisposing the patients to infection by antibiotic-resistant bacteria.17

The overall carriage rate of MDR-E was 87.8%. This finding was comparable with the studies reported in Arba Minch, Ethiopia (71%),16 Tanzania (94%),26 However, higher than studies done in Addis Ababa, Ethiopia (43%),17 Gondar, Ethiopia (38.7%),23 and Morocco (42.8%).27 This inconsistency might be due to indiscriminate use of antibiotics, poor hygienic practice in the study area, and differences in the study population.

Table 4 Multi-Drug Resistance Patterns of Enterobacteriaceae Isolates at Debre Berhan Comprehensive Specialized Hospital from November 2020 to March 2021

| Isolates (Number) | Number of Antimicrobials Resisted (n (%)) | R0 | R1 | R2 | R3 | R4 | R5 | R6 | ≥R7 | Total MDR Isolates (R≥3) |
|------------------|-----------------------------------------|----|----|----|----|----|----|----|-----|--------------------------|
| *E. coli* (n=221) |                                         | 1(0.5) | 12(5.4) | 27(12.2) | 30(13.6) | 32(14.4) | 27(12.2) | 21(9.5) | 71(32.2) | 181(81.9) |
| *Citrobacter* spp (n=4) |                                     | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(25.0) | 1(25.0) | 2(50.0) | 4(100.0) |
| *K. pneumoniae* (n=92) |                                      | 0(0.0) | 0(0.0) | 1(2.2) | 7(7.6) | 1(1.0) | 10(9.7) | 9(9.7) | 64(69.5) | 91(98.9) |
| *E. cloacae* (n=12) |                                          | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 2(16.6) | 2(16.6) | 8(66.6) | 12(100.0) |
| *K. oxytoca* (n=9) |                                              | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(11.1) | 8(88.9) | 9(100.0) |
| *C. diversus* (n=5) |                                               | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(20.0) | 2(40.0) | 2(40.0) | 5(100.0) |
| *M. morganii* (n=2) |                                               | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 2(100.0) | 2(100.0) |
| *P. stuartii* (n=1) |                                             | 0(0.0) | 1(100.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) |
| *K. ozaenae* (n=1) |                                               | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(100.0) | 1(100.0) |
| Total (n=347) |                                           | 1(0.3) | 13(3.7) | 28(8.1) | 37(10.6) | 33(9.5) | 41(11.8) | 36(10.3) | 158(45.5) | 305(87.8) |

Note: R0: resistance to no antibiotics, R1-7: resistance to 1, 2, 3, 4, 5, 6, and 7 antibiotics; ≥R3: resistance to 3 or more antibiotics from different classes.

Figure 2 The magnitude of ESBL-PE and non-E ESBL-PE at Debre Berhan Comprehensive Specialized Hospital from November 2020 to March 2021.
In the present study, a 100% MDR carriage rate was seen in *K. oxytoca, E. cloacae, Citrobacter spp, M. morganii, and C. diversus*. Being colonized by such multidrug-resistant bacteria is recognized to be a cause of infection and cross-transmission. Therefore, good hygienic practice and careful infection prevention should be implemented in the study setting.

The overall magnitude of ESBL-PE in this study was 47.3% 95% CI (42.0–52.2%). This result was comparable with the reports in Addis Ababa, Ethiopia (52%), Chad (46%), Madagascar (49%), Burkina Faso (42%), and India (43%). However, it was lower than the studies done in Egypt (65%), Tanzania (60%), Algeria (54%), Morocco (58%), and India (63%). In contrast, the current finding was higher than the studies done in Gondar, Ethiopia (16%), Arba Minch, Ethiopia (33%), Zimbabwe (41%), Spain (7.69%), Cyprus (21.4%), and Turkey (34%).

This

![Antibiotics susceptibility pattern of ESBL producing and non-ESBL-producing Enterobacteriaceae at Debre Berhan Comprehensive Specialized Hospital from November 2020 to March 2021.](https://doi.org/10.2147/IDR.S356807)

**Figure 3** Antibiotics susceptibility pattern of ESBL producing and non-ESBL-producing Enterobacteriaceae at Debre Berhan Comprehensive Specialized Hospital from November 2020 to March 2021.

**Abbreviations:** AMP, ampicillin; FOX, cefoxitin; GM, gentamicin; CIP, ciprofloxacin; STX, trimethoprim-sulfamethoxazole; IPM, imipenem; MIP, meropenem; AMC, amoxicillin-clavulanic acid; CTX, cefotaxime; CAZ, ceftazidime; CRO, ceftriaxone; TE, tetracycline; FEP, cefepime; C, chloramphenicol.

In the present study, a 100% MDR carriage rate was seen in *K. oxytoca, E. cloacae, Citrobacter spp, M. morganii, and C. diversus*. Being colonized by such multidrug-resistant bacteria is recognized to be a cause of infection and cross-transmission. Therefore, good hygienic practice and careful infection prevention should be implemented in the study setting.

The overall magnitude of ESBL-PE in this study was 47.3% 95% CI (42.0–52.2%). This result was comparable with the reports in Addis Ababa, Ethiopia (52%), Chad (46%), Madagascar (49%), Burkina Faso (42%), and India (43%). However, it was lower than the studies done in Egypt (65%), Tanzania (60%), Algeria (54%), Morocco (58%), and India (63%). In contrast, the current finding was higher than the studies done in Gondar, Ethiopia (16%), Arba Minch, Ethiopia (33%), Zimbabwe (41%), Spain (7.69%), Cyprus (21.4%), and Turkey (34%).

### Table 5 Distribution of ESBL-PE and MDR Isolates at Debre Berhan Comprehensive Specialized Hospital from November 2020 to March 2021

| Isolates (Number) | ESBL Positive n (%) | Total MDR n% |
|------------------|---------------------|--------------|
| *E. coli* (n=221) | 89 (49.2)           | 181 (59.3)   |
| *K. pneumoniae* (n=92) | 55 (61.1)         | 91 (29.8)   |
| *E. cloacae* (n=12) | 6 (50.0)             | 12 (3.9)     |
| *K. oxytoca* (n=9) | 8 (88.9)             | 9 (2.9)       |
| *C. diversus* (n=5) | 2 (40.0)            | 5 (1.63)     |
| *Citrobacter* spp (n=4) | 2 (50.0)              | 4 (1.3)       |
| *M. morganii* (n=2) | 0 (0.0)               | 2 (0.6)       |
| *P. stuartii* (n=1) | 0 (0.0)              | 0 (0.0)       |
| *K. ozaenae* (n=1) | 1 (100.0)            | 1 (0.0)       |
| **Total (n=347)** | **163 (53.4)**      | **305 (87.8)** |
discrepancy might be due to the difference in the study population, inappropriate use of antibiotics, variation in antibiotic resistance prevention measures, and variation in the method of ESBL detection.

The predominant ESBL-PE were *E. coli* 54.9% (n=90/164) and *K. pneumoniae* 33.5% (n=55/164). This result was lower than the previous findings from Addis Ababa, Ethiopia *E. coli* (70%), Tanzania *E. coli* (68%), Burkina Faso: *E. coli* (78%), Cyprus *E. coli* (94.4%), and Spain *E. coli* (77.7%). However, our finding was higher than the studies done in Gondar, Ethiopia *E. coli* (16.2%), Morocco *E. coli* (19.4%), and Korea *E. coli* (14.4%). The potential reason for the difference in magnitude of ESBL among *Enterobacteriaceae* could be several factors such as variation in type and frequency of isolates, sample size, study participants, and geographical location.

ESBL-PE were highly susceptible to meropenem (90.2%) and imipenem (89.0%). The highest susceptibility of carbapenems was in close agreement with the studies conducted in Addis Ababa, Ethiopia, Zimbabwe, and India where all reported a 100% sensitivity of carbapenems drugs. This highest susceptibility of ESBL-PE to carbapenems might be unavailability and high cost of carbapenems in healthcare settings and pharmacies of developing countries like Ethiopia and being last resort drug, limit the overuse and misuse of such antibiotics. ESBL-PE was also resistant to multiple antibiotics including aminoglycosides, sulfonamides, tetracycline, and other class antibiotics used. Similar findings were reported in Chad and Burkina Faso.

ESBL producers showed the highest resistance to gentamicin (91.2%) followed by tetracycline (79.9%) and trimethoprim-sulfamethoxazole (79.3%). ESBL producers also showed significant resistance to amoxicillin-clavulanic acid (74.4%), ciprofloxacin (65.2%), and cefoxitin (41.5%). This result was fairly similar to the findings reported in Arba Minch, Ethiopia, Morocco, Egypt, and Tanzania which all revealed ESBL-PE showed the highest resistance to gentamicin, tetracycline, and trimethoprim-sulfamethoxazole. The possible justification for the high co-resistance to other classes of antibiotics could be explained by the fact that gene codes for ESBL production are usually found on the same

| Variables | Categories | ESBL Carriage n (%) | COR (95% CI) | P-value | AOR (95% CI) | P-value |
|-----------|------------|---------------------|-------------|---------|-------------|---------|
| Age group | Neonates   | 23 (6.6)            | 3.92 (1.69–9.09) | 0.001   | 1.65 (0.9–4.79) | 0.67    |
|           | Children   | 31 (8.9)            | 1.69 (0.945–3.02) | 0.077   | 1.50 (0.28–8.09) | 0.63    |
|           | Adults     | 110 (31.7)          | 1            |         |             |         |
| History of antibiotic use in the past 3 months | Yes | 80 (23.1) | 7.35 (4.25–12.71) | 0.000 | 4.68 (2.28–9.58) | ≤0.001 |
|           | No         | 84 (24.2)           | 1            |         |             |         |
| History of hospitalization in the past 12 months | Yes | 62 (17.9) | 4.03 (2.36–6.86) | 0.000 | 1.02 (0.48–2.14) | 0.960   |
|           | No         | 102 (24.4)          | 1            |         |             |         |
| History of invasive procedure in the past 3 months | Yes | 37 (10.7) | 5.63 (2.63–12.09) | 0.000 | 2.28 (0.91–5.74) | 0.078   |
|           | No         | 127 (36.6)          | 1            |         |             |         |
| Admission ward | NICU | 23 (6.6) | 6.11 (1.91–19.55) | 0.02   | 4.86 (1.24–18.96) | 0.023    |
|           | Pediatric  | 31 (8.9) | 2.84 (1.01–7.77) | 0.039  | 0.80 (0.35–1.88) | 0.81    |
|           | Medical    | 39 (11.2)          | 1.45 (0.57–3.69) | 0.432  | 0.67 (0.23–1.83) |         |
|           | Surgery    | 39 (11.2)          | 1.69 (0.66–3.43) | 0.676  | 0.67 (0.23–1.83) |         |
|           | Gynecology and obstetrics | 17 (4.9) | 1.24 (0.44–3.49) | 0.078  | 0.67 (0.23–1.83) |         |
|           | Ophthalmology | 8 (2.3) | 1            |         |             |         |
| Chronic disease | Yes | 60 (17.3) | 4.45 (2.55–7.75) | 0.000  | 3.65 (1.87–7.13) | ≤0.001  |
|           | No         | 104 (30.0)          | 1            |         |             |         |

Note: 1 = reference.

Abbreviations: CI, confidence interval; COR, crude odd ratio; AOR, adjusted odd ratio; NICU, neonatal intensive care unit.
mobile genetic elements: that may also carry resistance genes for non-beta-lactam antibiotics.\textsuperscript{38} This finding indicates high fecal carriage ESBL-PE that were also resistant to most antibiotics which poses a high risk for nosocomial infection, dissemination of resistance genes and thus resistant pathogen in the hospital.

Socio-demographic and clinical data were analyzed as independent risk factors for ESBL-PE carriage. Multivariable logistic regression identified 3 variables as contributing factors for ESBL-PE carriage. Antibiotic use in the past 3 months, presence of chronic diseases, and admission in the neonatal intensive care unit showed statistically significant association with fecal carriage of ESBL-PE.

Participants who had a history of antibiotic use in the past 3 months were 4.68 times more likely carriers for ESBL-PE than those who had not used (AOR 4.68, 95% CI (2.28–9.58). This was similar to the studies conducted in Gondar, Ethiopia,\textsuperscript{23} Tanzania,\textsuperscript{22} Algeria,\textsuperscript{31} Burkina Faso,\textsuperscript{29} and Cyprus.\textsuperscript{5} This might indicate inappropriate use of antibiotics by the study participants which may result in selective pressure in the bacteria. This finally could have a role for ESBL carriage.

Another factor associated with the fecal carriage of ESBL-PE was the presence of chronic disease, consistent with the previous studies done in Arba Minch, Ethiopia,\textsuperscript{16} and Algeria.\textsuperscript{31} This might be due to participants with chronic diseases will have more exposure to antibiotics, and frequent hospital visits, which may lead to ESBL-PE carriage.

The third factor that contributed to the carriage of ESBL-PE was admission to a neonatal intensive care unit. Participants who had been admitted to NICU were 4.86 times more likely carriers for ESBL-PE than those who had been admitted to other wards. This finding is supported by the previous study conducted in Korea\textsuperscript{35} and Turkey.\textsuperscript{39} This could be due to the overuse of broad-spectrum antibiotics in the neonatal intensive care unit (NICU) to treat serious infections. Eventually, patients with ESBL-PE carriage might be sources for self and cross-transmission of resistance genes among other patients that could result in untreatable nosocomial infection in the study area.

This study indicates a high fecal carriage of ESBL-PE and MDR-E in the study area that needs strong infection prevention measures, careful selection of antibiotics after antimicrobial susceptibility test, and periodic surveillance of AMR at the study site. In addition, the finding informs the need for routine screening of ESBL, especially for patients admitted to the intensive care unit and patients who had chronic diseases in the study area for diagnostic and infection control or surveillance purpose which is not practiced yet in Ethiopia.

**Conclusions**

In this study, the fecal carriage of ESBL-PE and MDR-E was high among hospitalized patients. ESBL-PE showed a high level of resistance to many commonly used antibiotics. However, meropenem and imipenem were active against ESBL-PE. Antibiotic use in the past 3 months, admission in the neonatal intensive care unit, and presence of chronic disease showed statistically significant association with fecal carriage of ESBL-PE. Therefore, strict infection prevention measures should be implemented to limit infection and the spread of antimicrobial resistance strains in the study area.

**Data Sharing Statement**

Data that support the findings of the study are included.

**Acknowledgments**

We would like to acknowledge Debre Berhan Comprehensive Specialized Hospital Laboratory staff, for their technical and coordination support of the entire laboratory work. Our unforgettable acknowledgment goes to Debre Berhan University for their support particularly the Department of Medical laboratory science. Finally, we would like to acknowledge the study participants from which the sample was collected.

**Funding**

This research work was funded by Addis Ababa University, College of Health Science. Data collection, study design, data analysis, and interpretation were all done without the involvement of the funder.
Disclosure

The authors report the manuscript is prepared from the MSc thesis of D Shenkute. The authors report no conflicts of interest in relation to this work.

References

1. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18(5):263–272. doi:10.1016/j.molmed.2012.03.003
2. Andrew B, Kagirita A, Bazira J. Prevalence of extended-spectrum beta-lactamases-producing microorganisms in patients admitted at KRRH, Southwestern Uganda. Int J Microbiol. 2017;2017:1–5. doi:10.1155/2017/3183076
3. Mohamudha PR, Harish B, Parija S. AmpC beta lactamasmes among Gram negative clinical isolates from a tertiary hospital, South India. Braz J Microbiol. 2010;41(3):596–602. doi:10.1590/S1517-83822010000300009
4. Mulki SS, Ramamurthy K, Bhat S. Fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in intensive care unit patients. Indian J Crit Care Med. 2017;21(8):525–527. doi:10.4103/ijccm.IJCCM_112_17
5. Ruh E, Zakka J, Hiti K, et al. Extended-spectrum beta-lactamase, plasmid-mediated AmpC beta-lactamase, fluoroquinolone resistance, and decreased susceptability to carbapenems in Enterobacteriaceae: fecal carriage rates and associated risk factors in the community of Northern Cyprus. Antimicrob Resist Infect Cont. 2019;8(1):1–10.
6. Mahamat OO, Tidjani A, Lounnas M, et al. Fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital and community settings in Chad. Antimicrob Resist Infect Control. 2019;8(1):1–7. doi:10.1186/s13756-018-0426-x
7. Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol. 2006;9(5):466–475.
8. Rolain J-M. Food and human gut as reservoirs of transferable antibiotic resistance encoding genes. Front Microbiol. 2013;4:1–10. doi:10.3389/fmicb.2013.00173
9. Lynch III JP, Clark NM, Zhanell GG. Evolution of antimicrobial resistance among Enterobacteriaceae (Focus on extended spectrum beta-lactamases and carbapenemases). Expert Opin Pharmacother. 2013;14(2):199–210. doi:10.1517/14656566.2013.763030
10. Friedman ND, Carmeli Y, Walton AL, Schwaber MJ. Carbapenem-resistant Enterobacteriaceae: a strategic roadmap for infection control. Infect Control Hosp Epidemiol. 2017;38(5):580–594. doi:10.1017/ice.2017.42
11. Islam S, Selvarangan R, Kanwar N, et al. Intestinal carriage of third-generation cephalosporin-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae in healthy US children. J Pediatr Infect Dis Soc. 2017;7(3):234–240. doi:10.1093/jpids/pix045
12. Pilmis B, Cattoir V, Lecointe D, et al. Carriage of extended-spectrum beta-lactamase-and carbapenemase-producing Enterobacteriaceae in French hospitals: the PORTABLSE study. FEMS Immunol Med Microbiol. 2018;98(3):247–252. doi:10.1093/fimicb/fin167
13. Sonda T, Kumburu H, van Zwetselaar M, et al. Meta-analysis of proportion estimates of extended-spectrum beta-lactamase and carbapenem resistance among Enterobacteriaceae in East Africa hospitals. Antimicrob Resist Infect Control. 2016;5(1):1–9. doi:10.1186/s13756-016-0177-4
14. Vialle-Valentin C, Lecates R, Zhang F, Desta A, Ross-Degnan D. Predictors of antibiotic use in African communities: evidence from medicines household surveys in five countries. Trop Med Int Health. 2012;17(2):211–222. doi:10.1111/j.1365-3156.2011.02895.x
15. Abayneh M, Worku T. Prevalence of multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing gram-negative bacilli: a meta-analysis report in Ethiopia. Drug Target Insights. 2020;14(1):1–10. doi:10.33393/dti.2020.2170
16. Kibwana UO, Majigo M, Kamori D, Manyahi J. High fecal carriage of extended Beta Lactamase producing Enterobacteriaceae among adult patients admitted in referral hospitals in Dar Es Salaam, Tanzania. BMC Infect Dis. 2020;20(1):1–7. doi:10.1186/s12879-020-05272-4
17. Bayleeyeg B, Fisaha R, Kasew D. Fecal carriage of extended spectrum beta-lactamase producing Enterobacteriaceae among HIV infected children at the University of Gondar comprehensive specialized hospital Gondar, Ethiopia. AIDS Res Ther. 2021;18(1):1–9. doi:10.1186/s12981-021-00347-x
18. Negussie A, Tadesse M, Tadesse Z, et al. Rectal carriage of extended-spectrum beta-lactamase-and carbapenemase-producing Enterobacteriaceae in Ethiopian patients with community-onset gastrointestinal complaints: a hospital-based cross-sectional study. Antimicrob Resist Infect Control. 2017;6(1):1–7. doi:10.1186/s13756-017-0219-7
19. Telleke MG, Blomberg B, Kommedal Ø, Maselle SY, Langeland N, Moyo SJ. High prevalence of faecal carriage of ESBL-producing Enterobacteriaceae among children in Dar Es Salaam, Tanzania. PLoS One. 2016;11(12):1–13.
27. Girlich D, Bouhat N, Poirel L, Benouda A, Nordmann P. High rate of faecal carriage of extended-spectrum β-lactamase and OXA-48 carbapenemase-producing Enterobacteriaceae at a university hospital in Morocco. *Clin Microbiol Infect*. 2014;20(4):350–354. doi:10.1111/1469-0691.12325

28. Andriatahina T, Randrianirina F, Hariniana ER, et al. High prevalence of fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric unit in Madagascar. *BMC Infect Dis*. 2010;10(1):1–8. doi:10.1186/1471-2334-10-204

29. Ouedraogo AS, Sanou S, Kissou A, et al. Fecal carriage of Enterobacteriaceae producing extended-spectrum beta-lactamases in hospitalized patients and healthy community volunteers in Burkina Faso. *Microb Drug Resist*. 2017;23(1):63–70. doi:10.1089/mdr.2015.0356

30. Chaudhary U, Agarwal S, Raghuraman K. Identification of extended spectrum beta lactamases, AmpC and carbapenemase production among isolates of Escherichia coli in North Indian tertiary care centre. *Avicenna J Med*. 2018;8(2):46–50. doi:10.4103/ajm.AJM_156_17

31. Medboua-Benbalagh C, Touati A, Kerma S, et al. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae strains is associated with worse outcome in patients hospitalized in the pediatric oncology unit of Beni-Messous hospital in Algiers, Algeria. *Microb Drug Resist*. 2017;23(6):757–763. doi:10.1089/mdr.2016.0153

32. Babu R, Kumar A, Karim S, et al. Faecal carriage rate of extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospitalised patients and healthy asymptomatic individuals coming for health check-up. *J Glob Antimicrob Resist*. 2016;6:150–153. doi:10.1016/j.jgar.2016.05.007

33. Magwenzi MT, Gudza-Mugabe M, Mujuru HA, Dangarembizi-Bwakura M, Robertson V, Aiken AM. Carriage of antibiotic-resistant Enterobacteriaceae in hospitalised children in tertiary hospitals in Harare, Zimbabwe. *Antimicrob Resist Infect Control*. 2017;6(10):1–7. doi:10.1186/s13756-016-0155-y

34. Pérez CD-A, López-Fresneña N, Carlavilla ALR, et al. Local prevalence of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in Klebsiella pneumoniae: a prevalence survey in a Spanish University Hospital. *BMJ open*. 2019;9(3):1–6. doi:10.1136/bmjopen-2019-030833

35. Ko YJ, Moon H-W, Hur M, Yun Y-M. Risk factors of fecal carriage with extended-spectrum β-lactamase-producing Enterobacteriaceae in hospitalized patients. *Am J Infect Control*. 2013;41(12):1241–1243. doi:10.1016/j.ajic.2013.05.018

36. Wilmore SS, Kranzer K, Williams A, et al. Carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in HIV-infected children in Zimbabwe. *J Med Microbiol*. 2017;66(5):609–615. doi:10.1099/jmm.0.000474

37. Ouchar Mahamat O, Tidjani A, Louanne M, et al. Fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital and community settings in Chad. *Antimicrob Resist Infect Control*. 2019;8(1):169. doi:10.1186/s13756-019-0626-z

38. Ghaforian S, Sadeghifard N, Soheili S, Sekawi Z. Extended spectrum beta-lactamases: definition, classification and epidemiology. *Curr Issues Mol Biol*. 2015;2015(17).

39. Kiremitci A, Dinleyici EC, Yargic ZA, Durmaz G, Tekin N. Prevalence and risk factors of fecal carriage of Extended-Spectrum β-Lactamase (ESBL) -producing Enterobacteriaceae in hospitalized and ambulatory children. *J Pediatr*. 2011;5(2):54–58.